Is Erdafitinib a targeted drug or a chemotherapy drug?

Erdafitinib (Erdafitinib) is a targeted therapy drug rather than a traditional chemotherapy drug. Targeted therapy is an innovative method in the field of cancer treatment. Compared with traditional chemotherapy drugs, it is more specific and can more accurately intervene in the growth and spread of cancer cells and reduce the impact on normal cells.

Erdafitinib mainly acts on the kinases of the fibroblast growth factor receptor (FGFR) family. FGFR is a type of receptor that plays a key role in cell growth and differentiation. In some cancers, abnormal activation of FGFR is related to abnormal proliferation of cancer cells. Erdafitinib blocks the signaling pathways of cancer cells by inhibiting the activation of FGFR, thereby inhibiting the growth and spread of cancer cells.

Compared with traditional chemotherapy drugs, targeted therapy has higher specificity and acts more specifically on cancer cells. This makes targeted therapy drugs less likely to affect normal cells, alleviates the common side effects of many traditional chemotherapy drugs, and improves patients' quality of life.

Patients taking erdafitinib are typically those with advanced or metastatic urothelial carcinoma (UC), a rare but aggressive form of cancer. The drug was developed to meet the need for treatment of this type of cancer and provide more effective and personalized treatment options.

Erdafitinib is not currently available in the country, so patients cannot purchase it domestically and need to purchase erdafitinib through foreign channels. The original drug of erdafitinib is mainly the Hong Kong version of the original drug, with a price of more than 20,000, and needs to be purchased through a Hong Kong pharmacy. The generic drugs are relatively cheaper, mainly the Laos version and the Bangladesh Yaopin International version, with a price of about 1,000 to 2,000, and the ingredients of the original drug and the generic drug are basically the same.